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Transition state-based ST6Gal 
I inhibitors: Mimicking the 
phosphodiester linkage with a 
triazole or carbamate through an 
enthalpy-entropy compensation
Andrew P. Montgomery1, Danielle Skropeta1,2,3 & Haibo Yu  1,2,3
Human β-galactoside α-2,6-sialyltransferase I (ST6Gal I) catalyses the synthesis of sialylated 
glycoconjugates. Overexpression of ST6Gal I is observed in many cancers, where it promotes 
metastasis through altered cell surface sialylation. A wide range of sialyltransferase inhibitors have 
been developed, with analogues structurally similar to the transition state exhibiting the highest 
inhibitory activity. To improve synthetic accessibility and pharmacokinetics of previously reported 
inhibitors, the replacement of the charged phosphodiester linker with a potential neutral isostere such 
as a carbamate or a 1,2,3-triazole has been investigated. Extensive molecular dynamics simulations 
have demonstrated that compounds with the alternate linkers could maintain key interactions with 
the human ST6Gal I active site, demonstrating the potential of a carbamate or a 1,2,3-triazole as a 
phosphodiester isostere. Free energy perturbation calculations provided energetic evidence suggesting 
that the carbamate and 1,2,3-triazole were slightly more favourable than the phosphodiester. Further 
exploration with free energy component, quasi-harmonic and cluster analysis suggested that there is an 
enthalpy-entropy compensation accounting for the replacement of the flexible charged phosphodiester 
with a neutral and rigid isostere. Overall, these simulations provide a strong rationale for the use of 
a carbamate or 1,2,3-triazole as a phosphodiester isostere in the development of novel inhibitors of 
human ST6Gal I.
Sialic acid (N-acetylneuraminic acid, Neu5Ac) is one of the body’s most important sugars next to glucose1. 
Sialylation, the addition of sialic acid to cell surface molecules via the glycosyltransferase (GT) enzymes known 
as sialyltransferases (STs), is integral to cell function, governing numerous important biological processes includ-
ing cell–cell recognition, protein targeting, cell adhesion, and fertilisation2–4. However, abnormal sialylation is 
strongly associated with cancer, with hypersialylation of up to 30–40% seen in many cancers, along with marked 
upregulation of ST activity. This has been directly correlated with an increased metastatic potential of tumours 
and poor patient prognosis5,6. Upregulation of STs has also been shown to produce cellular resistance in both 
paclitaxel and cisplatin treatment in human ovarian and colorectal cancer cell lines, along with reducing treat-
ment efficacy7. Thus the critical role of STs in the process of tumour metastasis as well as drug resistance demon-
strates that inhibitors of STs could be used either alone as anti-metastatic agents, or in combination with existing 
drugs to enhance their sensitivity against resistant tumours8.
In humans, there are 20 different STs each of which share a common sugar nucleotide donor, cytidine 
5ʹ-monophosphate Neu5Ac (CMP-Neu5Ac)2,9. STs are classified into one of four groups based on the position 
and identity of the glycosyl acceptor (galactose, N-acetylgalactosamine or sialic acid) to which sialic acid is trans-
ferred: ST3Gal I-VI, ST6Gal I-II, ST6GalNAc I-VI, and ST8Sia I-VI2,3. Each ST subtype controls the synthesis 
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of specific sialylated structures with unique biological roles, therefore it is crucial that selective inhibitors are 
developed.
Herein we focus on human β-galactoside α-2,6-sialyltransferase I (ST6Gal I), which is one of the two subfam-
ilies of the ST6 family that belongs to the GT29 family (http://www.cazy.org)10. ST6Gal I catalyses the transfer of 
a Neu5Ac residue to the 6ʹ-hydroxyl group of the terminal Gal residues of the disaccharide Galβ[1,4]GalNAc3,11. 
ST6Gal I mediated sialylation can modulate protein conformation, oligomerisation and/or receptor internalisa-
tion12, depending on the substrate targeted. Overexpression of ST6Gal I is observed in several types of cancers 
including lung, cervical, ovarian, pancreatic, breast and colon carcinoma13–16. It has been recently reported that 
ST6Gal I promotes a cancer stem cell (CSC) phenotype, with the activity of ST6Gal I critical for CSC behaviours 
including tumour spheroid growth, chemoresistance and tumour initiating potential16. Additionally, overexpres-
sion of ST6Gal I has been suggested to promote cancer cell metastasis through altered sialylation patterns affect-
ing the function of β1 integrin17,18. ST6Gal I also has an important role in galectin regulation, via the sialylation 
of their galactose-containing substrates12,13. For instance, α-2,6 sialylation of the galectin substrates Fas19 and 
TNFR120 death receptors have been shown to hinder the apoptosis process, thus identifying ST6Gal I overex-
pression as an inhibitor of cell death pathways. It has also been recently demonstrated that ST6Gal I has a role in 
promoting tumour cell survival within serum-depleted environments, such as those within the hypovascularised 
regions of large, solid tumours21.
The catalytic mechanism of human ST6Gal I (Fig. 1) follows a classical SN2-like direct displacement mecha-
nism for inverting GTs11,22. It is facilitated by the catalytic base His370, which promotes the nucleophilic attack on 
the sialyl donor anomeric carbon by deprotonating the galactose 6ʹ-hydroxyl of the acceptor23,24. This generates 
an oxocarbenium-like transition state (TS), followed by CMP acting as a leaving group. The β-configuration at 
the anomeric carbon of the donor is inverted in the final product24. This is supported by a model of the Michaelis 
complex generated from the glycan binding mode observed in the crystal structure of human ST6Gal I25.
The overexpression of ST6Gal I in various cancers has resulted in the development of a diverse range of ST 
inhibitors26–28. Of these, analogues mimicking the proposed oxocarbenium ion-like TS of the donor (Fig. 1) exhibit 
the highest affinity to STs29,30. TS analogue inhibitors incorporating a 2-deoxy-2,3-didehydro-N-acetylneuraminic 
acid (Neu5Ac2en) moiety are amongst the most potent inhibitors. The TS-like characteristics are captured with 
the C2-C3 double bond mimicking the planar anomeric carbon and an extra carbon between the anomeric car-
bon and CMP leaving group to mimic the elongated distance in the TS29,31. Various strategies have been adopted 
to increase the potencies of these inhibitors. Derivatives which explore variations of the glycerol side chain of 
the Neu5Ac2en moiety produced the greatest inhibitory activity. Of these, phenoxy derivative 1 (Fig. 2) is one of 
the most potent TS analogue inhibitors reported to date (Ki = 29 nM for rat liver α-2,6-ST)32. More synthetically 
assessable derivatives that incorporate an aryl replacement of the Neu5Ac2en moiety have comparable activity to 
the phenoxy derivative 129,30,33. Of these the (R)-isomer of the phenoxy derivative 2 (Fig. 2) was a potent inhib-
itor of rat liver α-2,6-ST (Ki = 70 nM)29 and human ST6Gal I (Ki = 19 nM)34 and is the lead compound herein. 
Figure 1. Proposed reaction scheme for the catalytic mechanism of human ST6Gal I. R represents a glycan 
chain of a glycoconjugate. Replicated from Montgomery, A., Szabo, R., Skropeta, D. & Yu, H. Computational 
characterisation of the interactions between human ST6Gal I and transition-state analogue inhibitors: insights 
for inhibitor design. J. Mol. Recogn 29, 210–222, doi:10.1002/jmr.2520 (2016) with permission from Wiley.
www.nature.com/scientificreports/
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Recently, cyclopentyl34 and amide35 ST inhibitors have been reported with comparable nanomolar activity to the 
phenoxy lead derivative (2) against human ST6Gal I.
Many of the above inhibitors were designed with limited knowledge of the target ST structure. The recent char-
acterisation of the mammalian ST crystal structures, in particular that of human ST6Gal I25 and human ST8Sia 
III36, has facilitated the use of computational modelling to aid in the design of new selective ST inhibitors. In this 
work, we use computational modelling to investigate the effect of replacing the charged phosphodiester linkage 
of TS analogue ST inhibitors. This is being investigated, as while contributing to potency37 the phosphodiester 
linkage may potentially contribute to low bioavailability, loss of activity due to cleavage by phosphatases or insta-
bility in the ST active site38,39. To build upon our previous work40,41, molecular dynamics (MD) simulations and 
binding free energy calculations via the free energy perturbation (FEP) method will be undertaken to investigate 
the effect of replacing the phosphodiester linker of our lead compound 2, with either a 1,2,3-triazole (3; Fig. 2) 
or carbamate (4; Fig. 2), has on binding to human ST6Gal I. Force field parameters compatible with the 
CHARMM PARAM36 force field for the ligands will be developed42. Through equilibrium MD simulations the 
conserved interactions as well as potential differences between each compound will be compared. Furthermore, 
relative binding free energy calculations will be used to study the effect of the linker on binding affinity.
Methods
Force field development. Force fields generated from the CHARMM General Force Field (CGenFF)43 
using the paramchem interface (https://cgenff.paramchem.org) for the phosphodiester-linked 2 and the corre-
sponding 1,2,3-triazole-linked 3 and carbamate-linked 4 derivatives (Fig. 2) were optimised using the GAAMP 
method44. The partial atomic charges (see Supplementary Fig. S1 and Table S1) and identified “soft” dihedrals, 
which were not already represented in the CHARMM and CGenFF force fields or that experienced a significant 
penalty score from paramchem, were optimised (see Supplementary Fig. S2).
Molecular dynamics simulations. All MD simulations were prepared using VMD version 1.9.245. An 
overview of all simulations is given in Supplementary Table S2. Simulation of human ST6Gal I (PDB id: 4JS2)–
inhibitor complexes with the reported phosphodiester-linked compound 2 and the proposed 1,2,3-triazole 
and carbamate-linked derivatives (3 and 4 respectively; Fig. 2) were undertaken to determine if a carbamate 
or 1,2,3-triazole is a suitable replacement for the phosphodiester linker used in previously reported inhibitors. 
The initial structure for the ST6Gal I–inhibitor complexes was taken from previously reported docking stud-
ies40. Additionally, simulations of each inhibitor in a water box were also performed to determine the effect of 
linker flexibility. Prior to simulation being undertaken PROPKA 3.146 was used to predict the protonation state of 
ST6Gal I residues and ionisable ligand groups at pH 7.0.
Preparation of each simulation involved solvating the system in a box of water molecules, which extended 
approximately 9 Å from the surface of the protein, resulting in each system being solvated in an 82 Å × 82 Å × 82 Å 
cubic TIP3P47 water box. Each box was neutralised with counter ions of Na+ and Cl−, with the salt (NaCl) con-
centration set to 0.15 mol/L. Simulations were carried out using the NAMD 2.9 package48. The protein was rep-
resented with the non-polarisable CHARMM PARAM36 force field49. The force field for each ligand were those 
optimised using the GAAMP method44. All systems were simulated in periodic boundary conditions using 
the Langevin algorithm for maintaining the temperature at 298.15 K, and the Langevin Piston Nose–Hoover 
method50,51 for maintaining a constant pressure of 1.0 bar. The electrostatic interactions were calculated using the 
Particle Mesh Ewald method52. The van der Waals forces were treated with a cut-off of 12 Å and a smoothening 
function between 10 and 12 Å. All of the covalent bonds involving hydrogen were kept rigid with the RATTLE 
algorithm53. The integration time step was set to 1.0 fs, 2.0 fs and 4.0 fs for bonded, non-bonded and long-range 
electrostatics, respectively.
Equilibrium simulations for all human ST6Gal I-inhibitor complex systems were initially undertaken. During 
these simulations, a harmonic restraint was placed upon all Cα atoms of human ST6Gal I, with a decreasing 
Figure 2. Development of the phosphodiester-linked lead compound (2) and the analogous 1,2,3-triazole- (3) 
and carbamate- (4) linked derivatives.
www.nature.com/scientificreports/
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force constant from 32.0 to 1.0 kcal/mol/Å2 over 10 ns. This decrease was achieved gradually by halving the force 
constant for each respective 1 ns interval until a force constant of 1.0 kcal/mol/Å2 was obtained (i.e. 32.0, 16.0 
… 1.0 kcal/mol/Å2). A force constant of 1.0 kcal/mol/Å2 was then applied for the remainder of the 10 ns ther-
mal equilibration. The simulations were further continued for 90 ns without any restraints (see Supplementary 
Table S2). The inhibitor only simulations (see Supplementary Table S2) were performed for 20 ns with a harmonic 
restraint placed upon one atom of the corresponding ligand, with a force constant of 32 kcal/mol/Å2. To perform 
trajectory analysis, snapshots were saved every ps (i.e. every 1,000 steps). Replicates of each simulation from 
different starting coordinates were generated by starting each simulation with three different initial minimisation 
steps (i.e. 2,000, 2,500 and 3,000 steps) and initiated with different velocities. In total, 2.2 μs of MD simulations 
were performed.
Simulation trajectory analysis. To monitor the global properties of the structural evolution during MD 
simulations, the atomic positional root-mean-square deviations (RMSD) with respect to a reference structure and 
the atomic positional root-mean-square fluctuations (RMSF) were calculated using VMD45.
Hydrogen bond interactions were analysed according to a geometric criterion. A hydrogen bond was defined 
by a minimum donor–hydrogen–acceptor angle of 120° and a maximum heavy atom distance of 3 Å. Hydrophobic 
contacts were also analysed according to a geometric criterion of a maximum distance of 4 Å between hydropho-
bic atom pairs. To identify these interactions CHARMM version 38a154 was utilised.
The quasi-harmonic approximation55–57 was used to examine the loss of configurational entropy of each 
ligand upon binding to human ST6Gal I. This analysis was performed, using CHARMM version 38a154, for tra-
jectories encompassing 11–100 ns (11–55 ns and 56–100 ns were also performed to monitor convergence; See 
Supplementary Table S3) of each ligand in complex with human ST6Gal I and trajectories encompassing 1–20 ns 
(1–10 ns and 11–20 ns were also performed to monitor convergence; See Supplementary Table S3) of the ligand 
simulations. Prior to the analysis, the Cartesian coordinates of the ligands were aligned after least-squares fit 
superposition of the heavy atoms of all configurations onto the initial structure, to eliminate the overall trans-
lation and rotation. The change in configurational entropy (ΔSconf) was determined based on the following 
relationship:
Δ = − .S S S (1)conf (complex) (free)
Using the structures obtained from the MD simulations, conformational cluster analysis was performed for 
the ligands using MMTSB tools58. Clusters were identified using k-means clustering with an RMSD threshold for 
ligand heavy atoms of 1.6 Å. For each simulation, cluster analysis was based on combined trajectories of every 
10 ps of triplicate simulations. This resulted in 27,000 structures used in the analysis of the complexed simulations 
and 6,000 structures for the ligand only simulations.
Free energy perturbation calculations. All free-energy perturbation (FEP) calculations described 
herein were carried out using the NAMD 2.10 package48. The simulation parameters were as per the MD simu-
lation method described above. Depending on the calculation the starting structure was taken from the ST6Gal 
I-inhibitor simulations of the (R)-diastereomers of either the phosphodiester-linked lead compound (R)-2 
or the carbamate-linked derivative (R)-4 and temperature was maintained at either 288.15 K or 298.15 K (see 
Supplementary Table S2).
Each calculation utilised a dual ligand approach, where a ligand is mutated to an analogue in the human 
ST6Gal I binding site and the reverse mutation is performed simultaneously on the analogue in bulk water in the 
same system (Fig. 3). This approach has been undertaken to minimise potential electrostatic finite-size effects 
posed by the change in charge state when the (R)-diastereomer of the phosphodiester-linked lead compound 
2 (net charge of -2e) is perturbed to the (R)-diastereomer of either the 1,2,3-triazole- 3 or carbamate-linked 4 
derivatives (net charge of -1e) (Fig. 3)59,60. In this approach, the overall charge of the system remains constant. 
This allows for the reduction of errors arising from the large solvation energy of charged ligands and potential 
Figure 3. The thermodynamic cycle used (a) and a schematic representation of the perturbation performed (b) 
in the phosphodiester to carbamate FEP calculations. Phos and the yellow circle represent the phosphodiester-
linked lead compound (R)-2, Carb and the red square represent the carbamate-linked derivative (R)-4, and E 
represents human ST6Gal I.
www.nature.com/scientificreports/
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artefacts from the use of periodic boundary conditions. A similar approach has been successfully employed to 
handle changes in charge state in several different biomolecular systems61.
Using the dual ligand approach, the change in the binding free energy due to linker mutation with perturba-


















In the FEP method, one introduces a hybrid Hamiltonian, H(λ) = (1 − λ)H0 + λH1, where H0 represents the 
Hamiltonian for the initial state and H1 for the final state. The interval between 0 and 1 is divided into n subinter-
vals (λi, where i = 1, …, n – 1), and for each subinterval the free energy difference is calculated from the ensemble 
average, ΔΔGex,i = −kBT ln < exp[−(H(λi+1) − H(λi))/kBT > λi. The free energy difference between initial and 
final states is obtained from the sum, ΔΔG = Σi ΔΔGex,i. Alchemical transformations were carried out with 20 
uniformly distributed λ values between 0 and 1 (0.0, 0.05, 0.1, …, 0.9, 0.95, 1.0), with the transformation simu-
lated in reverse directions beginning from the 0.×5 λ values (e.g. 0.0 ← 0.05 → 0.1). To prevent the occurrence 
of singularities at values of λ where an atom disappears/appears, a soft-core potential with α = 4.0 Å2 was used to 
reshape the Lennard-Jones potential into a form devoid of singularity when λ approaches either 0 or 162,63.
Each λ window underwent initial 5000 energy minimisation steps followed by 1 ns equilibration simulation 
to provide starting coordinates. Each window was then subsequently simulated for multiple ns with a harmonic 
restraint placed on the centre of mass of ST6Gal I. A harmonic restraint was also applied to one atom from the ligand 
in the bulk. These restraints were applied to prevent association of the ligand in the bulk and ST6Gal I and had no 
effects on the calculated binding free energy difference. Both restraints used a force constant of 32 kcal/mol/Å2. 
In total 1.02 μs of FEP simulations were performed.
Results and Discussion
1,2,3-Triazole- and carbamate-linked (R)- and (S)-diastereoisomers maintain consistent binding 
site contacts with human ST6Gal I when compared to their phosphodiester derivative. 
Hydrogen bond and hydrophobic contact analysis of phosphodiester- and carbamate-linked (R)-diastereomers 
has previously been published40. These simulations were performed using ligand force fields generated using 
the general AMBER force field (GAFF)64 and with human ST6Gal I represented with the non-polarisable 
CHARMM PARAM36 force field49. In this work, a force field parameterisation compatible with the CHARMM 
PARAM36 force field was carried out for the ligands. We have undertaken simulation of both the (R)- and 
(S)-diastereoisomers of the phosphodiester- (2), 1,2,3-triazole- (3) and carbamate-linked (4) derivatives (Fig. 2) 
in complex with human ST6Gal I with the newly developed force field.
The MD simulations of each complex showed a stable trajectory with the positional RMSD of backbone Cα 
atoms being 1.5–2.0 Å for each simulation (see Supplementary Figs S3–S8). RMSFs for the Cα atoms, were gen-
erally consistent across all simulations (see Supplementary Figs S3–S8). Larger RMSF values, across each simu-
lation, were observed for the flexible loop between Tyr355 and Tyr369. Large RMSF values were also observed 
for the regions between Gln235—Asn250 and Ser260—Ile295, which comprise the portion of the active site that 
is expected to interact with the sialyl acceptor. This can most likely be attributed to the phenoxy being within 
the proposed sialyl acceptor site. Across all simulations each ligand remained tightly associated with the human 
ST6Gal I active site. However, there was some variation in ligand position within this active site, which can be 
seen in the RMSD values that correspond to the heavy atoms of each ligand (see Supplementary Figs S3–S8). 
These fluctuations can be attributed to the m-phenoxy substituent, which depending upon the simulation either 
rotated to maintain contacts with the sialyl acceptor site or only weakly interacted with peripheral residues of this 
pocket, resulting in positional fluctuation.
Interactions in the human ST6Gal I-ligand complexes analysed were characterised by monitoring the hydro-
gen bonds and hydrophobic contacts (see Supplementary Tables S4–S15). Each simulation revealed similar inter-
actions with the ST6Gal I active site, which have been schematically illustrated in Fig. 4.
The cytidine moiety of each simulation’s respective compound maintained the hydrogen bonding interactions 
that were observed in the human ST6Gal I crystal structure25. An additional interaction observed in all simula-
tions was Lys376 acting as a hydrogen bond donor to the pyridine like nitrogen of the cytosine ring. There was 
also Ser189 acting as a hydrogen bond donor with the oxygen embedded within the furan ring in the simulations 
of the (S)-diastereomers (Fig. 4b). The hydrophobic contacts that were observed were most significant with the 
cytosine ring, which was shown to interact with Ala190 and have a proposed π-stacking interaction with Tyr354. 
The ribose ring was generally shown to have hydrophobic interactions with Phe211 and Leu372. It should be 
noted that in the simulations of the (R)-diastereomers only (Fig. 4a), a water bridge interaction between the free 
amine of the cytosine ring and the backbone carbonyl of Val352 was also observed.
In addition to the CMP moiety, each compound had two other conserved regions, the phosphonate and the 
Neu5Ac mimic. For the simulation involving the (R)-diastereomers the phosphonate was shown to hydrogen 
bond with His370 in all simulations and, Ala368 and Tyr369 in all simulations except TC1 (see Supplementary 
Table S8). The phosphonate in the simulations of the (S)-diastereomers occupied a different orientation within 
the ST6Gal I active site and was shown to hydrogen bond with Tyr354 in all simulations. This difference between 
the diastereomers is to be expected as the phosphonate is a substituent at the only varied chiral centre. This could 
also be an explanation to the higher level of potency observed for (R)-2 compared to (S)-2 when tested against rat 
α-2,6 ST29, which has been shown to have a high level of homology to the human equivalent23.
www.nature.com/scientificreports/
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The Neu5Ac mimic consists of two components, the aryl ring and its m-phenoxy substituent. The m-phenoxy 
substituent for the majority of the simulations was shown to be in, or oriented towards, the proposed sialyl accep-
tor site through observed hydrophobic contacts with Asn233, Gln235, Trp257, Pro259, Tyr275 and Tyr369. 
This was most evident for the (S)-diastereomers. More variation in this group’s position was observed for the 
(R)-diastereomers, with the phenoxy generally orientated to interact only with the residues on the periphery of 
the pocket, being Asn233, Tyr369 and His370. Notably of the three different classes of linker observed, it was 
the 1,2,3-triazole that showed both the (R)- and (S)-diastereomers with the same m-phenoxy interactions (see 
Supplementary Tables S9 and S11), suggesting the added rigidity of the linker favours direction towards the pro-
posed sialyl acceptor site. This is an important finding, as this site is expected to vary between the different ST 
subtypes, particularly those with different sialyl acceptors, and thus presents a potential route to the development 
of selective human ST6Gal I inhibitors.
The aryl ring of the Neu5Ac mimic was shown to have limited interactions with human ST6Gal I, with the 
(R)-diastereomers showing hydrophobic contacts with Tyr369 and His370 and the (S)-diastereomers with 
Leu236. Despite being limited these interactions are nevertheless important in directing the m-phenoxy towards 
the proposed sialyl acceptor site. This is clearly highlighted in the CL2 simulations (see Supplementary Table S2) 
where this aryl ring is shown to interact with Cys353, Tyr354 and Cys364 in a binding mode that does not see the 
m-phenoxy within the proposed sialyl acceptor site.
Figure 4. Schematic representation of conserved hydrogen bonds and hydrophobic contacts observed in the 
(R)-diastereomer- (a) and (S)-diastereomer-ST6Gal I complex (b) simulations. The consistent components of 
each inhibitor are shown as chemical structures. The orange box represents the different linkers. Interacting 
human ST6Gal I residues are represented as circles which are colour coded based on interaction type as 
follows: Red = hydrogen bond donor; Green = hydrogen bond acceptor; Blue = water bridged hydrogen 
bond; Grey = hydrophobic contact; Pink = hydrogen bond and hydrophobic contact. Dashed lines indicate 
hydrophobic contacts and dotted lines represent the hydrogen bonds shown in Supplementary Tables S4–S15.
www.nature.com/scientificreports/
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The only component of the potential ST inhibitors examined that varied was the group that links the CMP 
moiety to the Neu5Ac mimic. Consistent interactions were observed when comparing the phosphodiester linker 
to the 1,2,3-triazole- and carbamate linkers. In the simulations of the (R)-diastereomers, hydrogen bonds of the 
linkers with Asn212 and Tyr354 were observed. In the simulations of the (S)-diastereomers hydrogen bonds of 
the linkers with Asn212 were observed.
Analysis of the hydrogen bond and hydrophobic contacts of both the (R)- and (S)-diastereomers of the three 
different classes of compounds, has demonstrated that no matter which linker is used, key interactions of cytidine 
and the Neu5Ac mimic with the human ST6Gal I active site are able to be maintained. These results confirm our 
previous findings40 and provide further evidence that a carbamate or a 1,2,3-triazole may be a suitable isosteric 
replacement for the phosphodiester linkers that have been used in reported ST inhibitors.
Binding free energy calculations confirm 1,2,3-triazole and carbamate as isosteres of the phos-
phodiester linker. To build upon the results observed in the MD simulations on the thermodynamic level, 
FEP calculations were performed to study the relative binding affinities for compounds with three different link-
ers. These simulations involved the alchemical transformations of the phosphodiester-linked (R)-2 to either the 
1,2,3-triazole (R)-3 or carbamate-linked (R)-4 derivatives. To close the thermodynamic cycle in order to monitor 
the convergence, an additional transformation of the carbamate-linked (R)-4 to the 1,2,3-triazole-linked (R)-3 
was also performed. The results of the FEP calculations are summarised in Table 1.
The ΔΔGb values observed for the 288 K and 298 K calculations form a thermodynamic cycle which closes 
within a reasonable error of −1.5 kcal/mol and −0.8 kcal/mol respectively. These calculations indicate that there 
is only a slight difference in the free energy of binding between the carbamate- and 1,2,3-triazole-linked deriva-
tives, with the 1,2,3-triazole favoured. It was also demonstrated that when the phosphodiester linker of the lead 
compound is perturbed to either a carbamate or a 1,2,3-triazole, a slightly more favourable binding to ST6Gal I 
is observed (−1.7 kcal/mol and −1.4 kcal/mol respectively at 298.15 K), with the carbamate being slightly more 
preferential.
This result is surprising as the charge of the phosphodiester linker has been previously thought to be impor-
tant for binding, but to what extent is currently unknown29,32,34,35,38. It is expected that replacing the charged 
phosphodiester group with a neutral isostere could potentially result in the loss of favourable interactions with the 
binding site that are mediated by this charge. For example, in the MD simulations the phosphodiester linker was 
involved in three additional water mediated interactions that were not observed in those of the carbamate- and 
1,2,3-triazole-linked derivatives (see Supplementary Tables S4, S8, S12). Therefore, one would expect an impact 
on the binding free energy (ΔGb), particularly through enthalpy (ΔHb), if the charged phosphodiester linker 
were to be replaced. Based on the relatively similar binding free energies for compounds with three different 
linkers, we hypothesise that the more rigid isosteric linkers might achieve comparable binding affinities through 
a favourable entropy compensation.
The error analyses for the FEP simulations were carried out by calculated the standard error of the mean 
(SEM) based on each ns simulation segment (Table 1) and all simulations converged with an error of <1.0 kcal/
mol. RMSD of both protein backbone and complexed ligand were also monitored. RMSDs for Cα of ST6Gal I 
converged between 1.5 Å and 2.0 Å indicating that no significant change in the structure of the protein backbone 
occurred as one linker was perturbed to another. Across all simulations each ligand remained tightly associated 
with the ST6Gal I active site, with RMSD values that fluctuated between 1.0 Å and 3.0 Å observed. As with the 
MD simulations discussed above, this fluctuation was influenced by the m-phenoxy substituent, with it remaining 
fixed in the sialyl acceptor site for the lower RMSDs observed and with it orientated towards the sialyl acceptor 
site but not constantly located within it when larger RMSDs were observed.
Relative rigidity of the 1,2,3-triazole and carbamate linkers compensate for the enthalpic 
penalty that results from replacing the phosphodiester. To test our enthalpy-entropy compensa-
tion hypothesis proposed based on the FEP calculations, we calculated ΔΔHb and ΔΔSb from the ΔΔGb val-
ues observed at two different temperatures (Table 1)65. From this analysis, we were able to demonstrate that 
the replacement of the charged phosphodiester linker with either a neutral carbamate or 1,2,3-triazole indeed 
results in an enthalpic penalty (a positive ΔΔHb). In both cases this penalty was compensated for by a favourable 
entropy (a negative ΔΔSb). This supports our hypothesis of the resulting molecular rigidity created by the inclu-




288 Ka 298 Kb — —
2 → 4 −1.1 ± 0.8 −1.7 ± 0.4 10 ± 30 −20 ± 30
2 → 3 −0.3 ± 0.3 −1.4 ± 0.9 40 ± 30 −40 ± 30
4 → 3 −0.7 ± 1.0 −0.5 ± 0.3 −10 ± 30 10 ± 30
Table 1. Difference in binding free energy to human ST6Gal I of proposed ST inhibitors. Running average of 
ΔΔGb (kcal/mol) calculated at a288.15 K and b298.15 K, error reported is the SEM. cThe ΔΔHb (kcal/mol) and 
−TΔΔSb (kcal/mol) are calculated through finite-temperature difference from the ΔΔGb values for both the 
simulations carried out at 288.15 K and 298.15 K. The values reported are those for 298.15 K, error reported is 
the SEM.
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perturbation from the carbamate to the 1,2,3-triazole, the opposite relationship was observed where changing to 
a triazole was enthalpically favourable which compensated for an entropic penalty.
The effect of the entropic component of binding free energy to human ST6Gal I has also been demonstrated 
through quasi-harmonic analysis of the trajectories obtained from the MD simulations performed (Table 2). This 
analysis has shown that for both the (R)- and (S)-diastereomers, the phosphodiester-linked lead compound 2 has 
a larger configurational entropy penalty upon binding to human ST6Gal I when compared to the 1,2,3-triazole- 
3 and carbamate-linked 4 derivatives. Though the quasi-harmonic analysis only captures the configurational 
entropy of the ligands upon binding, while neglecting contributions from other factors, the relatively large differ-
ence observed supports the entropic compensation that was captured in the component analysis of the ΔΔGb val-
ues (Table 1). It can also be seen that there is comparatively a very small difference (that is within error) between 
the −TΔSconf values for the carbamate and 1,2,3-triazole (Table 2). However, the 1,2,3-triazole does exhibit a 
slightly larger value for both the (R)- and (S)-diastereomers supporting the entropic penalty observed when a 
carbamate is perturbed to a 1,2,3-triazole (Table 1).
Comparing the diastereomers it can be seen while there are no major differences between the diastereomers, 
the (S)-diastereomer in all three cases has a slightly larger entropic penalty for binding to ST6Gal I. This result 
reflects the slight differences in the binding modes of the diastereomers observed during the analysis of the MD 
simulations.
Overall both the free energy component analysis and the quasi-harmonic analysis have demonstrated that 
the conformational restriction, and thus entropic favourability for binding, imparted by the 1,2,3-triazole and 
carbamate linkers when compared to the phosphodiester linker is enough to compensate the resulting enthalpic 
penalty. This result has provided a strong rationale for the use of these two groups as isosteres of the phosphodi-
ester in the development of potential inhibitors of human ST6Gal I. Interestingly, while we have demonstrated the 
benefit of introducing conformational restriction to binding, there appears to be a limit to what can be tolerated. 
This is reflected in the carbamate being shown to be slightly more entropically favourable than the 1,2,3-triazole 
(Tables 1 and 2).
Conformational cluster analysis demonstrates different linker flexibilities. Additional clustering 
analysis was performed for the ligand conformations in the human ST6Gal I-ligand complex and in the aqueous 
solution. The most dominant cluster for each complex simulation (see Supplementary Fig. S9) showed similar 
positions for the cytidine and phenoxy substituents for both the (R)- and (S)-diastereomers. This supports the 
findings of the analysis of the protein-ligand interactions (Fig. 4). The conformations of these structures also 
provide an indication of the differing levels of flexibility of each linker, with the conformation of the 1,2,3-triazole 
derivatives being much more rigid and elongated when compared to the phosphodiester- and carbamate-linked 
counterparts. However, this conformational difference is much more obvious in the distribution of cluster pop-
ulation obtained from the ligand in water box simulations (see Supplementary Fig. S10). The distribution for the 
(R)-diastereomers shows the phosphodiester-linked ligand samples a much larger conformational space than 
both its carbamate- and 1,2,3-triazole-linked counterparts, as evidenced by the number of clusters identified. The 
distribution for the (S)-diastereomers shows a similar trend, however the difference between the phosphodiester 
and carbamate derivatives is not as large. The increased flexibility of the phosphodiester derivatives compared to 
the 1,2,3-triazole- and carbamate-linked derivatives provides further evidence to support the enthalpy-entropy 
compensation hypothesis.
It is worth noting that though the binding free energy differences are converged within 1.0 kcal/mol, a proper 
error propagation significantly increases the uncertainties in the enthalpic component (ΔΔHb) and entropic 
component (−TΔΔSb) (Table 1). Nevertheless, our calculations have demonstrated that these three types of 
inhibitors with different linkers have similar potencies against human ST6Gal I. Complementary analyses based 
on binding entropy calculations, quasi-harmonic and conformational cluster analyses highlighted the potential 
role of entropy in the binding of transition state-based ST6Gal I inhibitors. Experimentally, we are synthesis-
ing both the 1,2,3-triazole- and carbamate-linked derivatives and their predicted potency will be validated with 
experimental inhibition rates and kinetic constants. The enthalpy-entropy compensation hypothesis can be then 
validated by examining the temperature-dependent data.
Cpd ΔSconf (kcal/mol/K)a −TΔSconf (kcal/mol)b
(R)-2 −0.125 ± 0.009 37 ± 3
(S)-2 −0.14 ± 0.02 41 ± 6
(R)-3 −0.08 ± 0.01 23 ± 4
(S)-3 −0.09 ± 0.01 27 ± 4
(R)-4 −0.067 ± 0.007 20 ± 2
(S)-4 −0.09 ± 0.02 25 ± 6
Table 2. Configurational entropy change upon binding of phosphodiester-linked (2), 1,2,3-triazole-linked 
(3) and carbamate-linked (4) derivatives to human ST6Gal I. aArithmetic mean ΔSconf ± standard error of the 
mean (SEM) obtained from triplicate simulations of each compound. bArithmetic mean ΔSconf multiplied by 
−298.15 K ± SEM obtained from triplicate simulations of each compound.
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Conclusion
MD simulations and FEP calculations were performed to investigate the replacement of the charged phos-
phodiester linker used in reported TS analogue ST inhibitors with a neutral isostere, such as a carbamate or a 
1,2,3-triazole. MD simulations of the (R)- and (S)-diastereomers of three ligands, which only differed in the linker, 
complexed with human ST6Gal I or in a water box were performed. Hydrogen bonds and hydrophobic contacts 
of the ligands with human ST6Gal I were monitored over the course of the simulations and have demonstrated 
that no matter which linker is used, important interactions with the active site are able to be maintained. These 
results confirmed the findings of our previous work40, which was undertaken with a different set of force fields. 
Free energy perturbation calculations demonstrated that when the phosphodiester linker was perturbed to either 
a carbamate or a 1,2,3-triazole a slightly more favourable binding to human ST6Gal I was observed, with the car-
bamate being marginally more preferential. This result was a surprise considering the perceived importance of the 
phosphodiester linker. We rationalise this observation with a hypothesis of an enthalpy-entropy compensation, 
which is supported with free energy component analysis, quasi-harmonic and cluster analysis. These analyses 
demonstrated that the conformational restriction, and thus entropic favourability for binding, imparted by the 
1,2,3-triazole and carbamate linkers when compared to the phosphodiester linker is enough to compensate the 
resulting enthalpic penalty. The results of these simulations have provided a strong rationale for the use of a car-
bamate or 1,2,3-triazole as an isostere of the phosphodiester. We are currently exploring both potential isosteres 
synthetically with the aim to develop novel inhibitors of human ST6Gal I, improve synthetic accessibility and 
address potential pharmacokinetic problems.
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